Skip to main content

Table 1 The characteristics of MPNs in Malaysia

From: The epidemiology and clinical characteristics of myeloproliferative neoplasms in Malaysia

No

Characteristics

Total MPNs

JAK2 V617F positivea

JAK2 V617F negativea

p-value

N (%)

n (%)

n (%)

1.

Total patients, n

1010

644

222

 

2.

Age at diagnosis, year

 

 Mean (sd)

54.2 (14.88)

55.9 (13.39)

49.1 (16.59)

< 0.001

 

 95% CI for population mean

53.32, 55.16

54.90, 56.97

46.87, 51.26

 

3.

Sex

 

 Female

488 (48.3)

317 (49.2)

99 (44.6)

0.234

 

 Male

522 (51.7)

327 (50.8)

123 (55.4)

 

4.

Ethnic groupsb

 

 Malay

447 (44.2)

310 (48.1)

84 (37.8)

< 0.001

 

 Chinese

412 (40.8)

253 (39.3)

104 (46.8)

 
 

 Indian

65 (6.4)

32 (5.0)

24 (10.8)

 
 

 Native—Sabah

42 (4.2)

22 (3.4)

5 (2.3)

 
 

 Native—Sarawak

19 (1.9)

13 (2.0)

0 (0)

 
 

 Others

25 (2.5)

14 (2.2)

5 (2.3)

 

5.

MPN sub-types

 

 ET

408 (40.4)

232 (36.0)

123 (55.4)

< 0.001

 

 PV

385 (38.1)

300 (46.6)

49 (22.1)

 
 

 PMF

93 (9.2)

58 (9.0)

12 (5.4)

 
 

 HES

31 (3.1)

0 (0)

22 (9.9)

 
 

 MPN-U

80 (7.9)

48 (7.4)

11 (5.0)

 
 

 Others

5 (0.5)

1 (0.2)

2 (0.9)

 
 

 Not documented/missing

8 (0.8)

5 (0.8)

3 (1.3)

 

6.

Splenomegaly

 

 Yes

325 (32.2)

237 (36.8)

35 (15.8)

< 0.001

 

 No

680 (67.3)

405 (62.9)

186 (83.8)

 
 

 Not documented/missing

5 (0.5)

2 (0.3)

1 (0.4)

 

7.

Presenting vasomotor symptomsc

 

 Yes

218 (21.6)

154 (23.9)

36 (16.2)

0.015

 

 No

780 (77.2)

482 (74.8)

185 (83.3)

 
 

 Not documented/missing

12 (1.2)

8 (1.3)

1 (0.5)

 

8.

Presenting arterial thrombosisd

 

 Yes

209 (20.7)

149 (23.1)

28 (12.6)

< 0.001

 

 No

792 (78.4)

492 (76.4)

193 (86.9)

 
 

 Not documented/missing

9 (0.9)

3 (0.5)

1 (0.5)

 

9.

Presenting venous thrombosise

 

 Yes

35 (3.5)

28 (4.4)

4 (1.8)

0.082

 

 No

967 (95.7)

612 (95.0)

217 (97.7)

 
 

 Not documented/missing

8 (0.8)

4 (0.6)

1 (0.5)

 

10.

Presenting bleedingf

 

 Yes

67 (6.6)

40 (6.2)

14 (6.3)

0.956

 

 No

936 (92.7)

602 (93.5)

207 (93.2)

 
 

 Not documented/missing

7 (0.7)

2 (0.3)

1 (0.5)

 

11.

Incidental finding

 

 During medical attention for unrelated condition

494 (48.9)

324 (50.3)

109 (49.1)

0.324

 

 Health screening

118 (11.7)

69 (10.7)

32 (14.4)

 
 

 No

379 (37.5)

242 (37.6)

78 (35.1)

 
 

 Not documented/missing

19 (1.9)

9 (1.4)

3 (1.4)

 

12.

BM fibrosis

 

 Grade 0

157 (15.5)

94 (14.6)

38 (17.1)

0.202

 

 Grade 1

86 (8.5)

60 (9.3)

14 (6.3)

 
 

 Grade 2

48 (4.7)

33 (5.1)

12 (5.4)

 
 

 Grade 3

52 (5.1)

40 (6.2)

6 (2.7)

 
 

 Grade 4

21 (2.1)

12 (1.9)

4 (1.8)

 
 

 Suboptimal sample

83 (8.2)

50 (7.7)

24 (10.8)

 
 

 Not done

544 (53.9)

345 (53.6)

121 (54.5)

 
 

 Not documented/missing

19 (2.0)

10 (1.5)

3 (1.4)

 
  1. aJAK2 V617F mutation result was not reported for 144 patients
  2. bNatives from Sabah and Sarawak, and others are grouped together for Chi square test as the expected count must be at least 2
  3. cPresenting vasomotor symptoms include headache, transient neurologic or ocular symptoms, distal paraesthesias, erythromelalgia, and others
  4. dPresenting arterial thrombosis includes stroke/transient ischemic attack (TIA), acute coronary syndrome, digital gangrene, retinal artery occlusion, mesenteric artery thrombosis, and others
  5. ePresenting venous thrombosis includes hepatic or portal vein thrombosis, deep vein thrombosis (DVT), retinal vein thrombosis, sagittal sinus thrombosis, pulmonary embolism (PE), and others
  6. fPresenting bleedings include gastro intestinal tract (GIT) unspecified, post-surgical bleed, mucocutaneous, and others
Back to article page

Experimental Hematology & Oncology

ISSN: 2162-3619

Contact us